SeerPharma explores markets in India, China

In an interview with BioSpectrum, Mr Brad Roberts, partner and senior consultant, SeerPharma, says there is potential in the training sector in these countries

Mr Brad Roberts, partner and senior consultant, SeerPharma

Australia-based SeerPharma, which offers international quality management and compliance experience, and advice to support client's compliance management and productivity improvement across pharmaceutical, medical devices and biological industries, is planning its foray into India and China. Formed in 2001 with its headquarters in Melbourne, the company has a regional office in Singapore and strategic alliances in the UK and South Korea. It is now talking to companies in India and China to capitalize on the growth of the life sciences industry in these two countries.

Mr Brad Roberts, partner and senior consultant, SeerPharma, speaks to BioSpectrum about their plan to enter the India market during his visit as part of Victoria Government Super Trade Mission to India.

Are you planning to expand your business in India? If yes, then how do you plan to enter?

Mr Roberts: The purpose of SeerPharma's involvement in the trade mission was two-fold. Firstly, it was establishing whether there was a market for us in India. Secondly, assuming an opportunity existed, exploring the options available to take advantage of in this market.

SeerPharma sees several opportunities in India. During discussions with several companies as part of the trade mission, interest was expressed by them for using SeerPharma's expertise in GXP (GMP, GLP, GCP and GDP, etc.) and compliance consulting services to expand their existing offering, both horizontally and vertically, in the market. Similar interest was shown in our integrated quality assurance (iQA) and quality management system (QMS) products, and they are being pursued.